3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors of 3B BlackBio Dx Ltd (formerly Kilpest India Limited) met on May 29, 2026 and approved audited financial results for Q4 and FY 2025-26. The company reported strong growth with consolidated revenue increasing to Rs 14,191.81 Lakhs from Rs 9,646.86 Lakhs in the previous year, driven primarily by the diagnostic kits segment (Rs 13,111.81 Lakhs). Consolidated profit after tax rose to Rs 5,992.98 Lakhs from Rs 4,769.11 Lakhs. The Board recommended a final dividend of 50% i.e. Rs 5 per equity share of Rs 10 each for FY 2025-26, subject to shareholder approval at the ensuing AGM. The company also appointed M/s Ali Jain & Sharma as Internal Auditor for FY 2026-27. One-time M&A advisory fees of Rs 174.08 Lacs were incurred for the acquisition of Coris Bioconcept SRL, Belgium.
Strong financial performance with double-digit revenue and profit growth is positive for shareholders. The dividend recommendation signals confidence in future cash flows, though the stock price impact will depend on market expectations and current valuations.